文献速递白血病

成人费城染色体阳性急性淋巴细胞白血病伴p16基因缺失的临床分析

[Clinical analysis of adult Philadelphia chromosome-positive acute lymphoblastic leukemia with p16 gene deletion].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

回顾性分析80例初诊成人费城染色体阳性急性淋巴细胞白血病(Ph(+) ALL)患者,p16基因缺失率为31.3%。p16缺失组伴随高白细胞计数和CD20表达,诱导缓解率无差异,但3个疗程后MMR和CMR率更低、复发率更高,3年OS率和DFS率更低。25例p16缺失患者中14例行异基因造血干细胞移植,中位生存21个月,长于未移植组的12个月。

要点

  • 成人Ph(+) ALL中p16基因缺失率为31.3%,与高白细胞计数(WBC≥30×10(9)/L)和CD20表达相关。
  • p16缺失组3个疗程后MMR率和CMR率低于非缺失组,复发率高于非缺失组,3年OS率和DFS率低于非缺失组。
  • p16缺失患者中,伊马替尼与达沙替尼联合化疗的MMR、CMR及复发率无显著差异;14例行allo-HSCT者中位生存21个月,长于未移植组的12个月。

核心结论

  • 成人Ph(+) ALL伴p16基因缺失患者预后相对较差,二代酪氨酸激酶抑制剂(达沙替尼)的疗效较伊马替尼无明显优势,而异基因造血干细胞移植能够改善部分患者的生存。
  • 明确p16基因缺失状态对于评估预后和指导临床治疗决策有重要意义。

研究设计与样本

  • 回顾性分析80例初诊成人Ph(+) ALL伴p16基因缺失患者的临床特征、免疫表型、细胞遗传学、分子生物学改变及预后。

主要发现

  • 80例成人Ph(+) ALL中p16基因缺失率为31.3%。
  • p16缺失组较非缺失组初诊时高白细胞计数(WBC≥30×10(9)/L)更常见,高表达CD20,更易出现附加染色体异常,以累及7、8、19号染色体及der(22)较为常见。
  • 两组诱导缓解率比较差异无统计学意义(P=0.033);p16缺失组治疗3个疗程后MMR率和CMR率均低于非缺失组(P分别为0.034和0.036)。
  • p16缺失组复发率高于非缺失组(P=0.033);p16缺失组3年OS率和DFS率分别为37.1%和12.4%,低于非缺失组的54.1%和45.9%(P分别为0.037和0.026)。
  • p16缺失组中伊马替尼联合化疗者与达沙替尼联合化疗者的MMR、CMR率及复发率差异均无统计学意义(P值均>0.05);25例p16缺失患者中14例行allo-HSCT,中位OS为21个月,长于非移植组的12个月(P=0.030)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical implications of p16 gene deletion in adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) . Methods: Retrospective analysis of clinical, immunophenotypic, cytogenetics, molecular characteristics and prognosis of 80 newly diagnosed Ph(+) ALL patients with p16 deletion. Results: Of 80 adult Ph(+) ALL, the prevalence of p16 gene deletion was 31.3%. p16 gene deletion carriers frequently accompanied with high WBC counts (WBC≥30×10(9)/L) and CD20 expression. The incidence of complex chromosome abnormality in p16 gene deletion group was higher than that in non-deletion group, with alternations in chromosome 7, 8, 19 and der (22) more frequently observed. There was no difference occurred between patients with or without p16 gene deletion in complete remission (CR) rate following induction chemotherapy combined with tyrosine kinase inhibitors (TKIs) . However, after three cycles of chemotherapy, the MMR and CMR rate in the p16 gene deletion group was lower than patients with wild-type p16 gene (P=0.034, P=0.036) . The p16 gene deletion patients showed no significant differences in MMR, CMR and relapse rate between Imatinib or Dasatinib plus chemotherapy (P>0.05) . Deletion of p16 gene was significantly associated with poor outcomes including worse overall survival (OS) (37.1% vs 54.1%, P=0.037) , lower disease free-survival (DFS) (12.4% vs 45.9%, P=0.026) , and increased cumulative incidence of relapse (P=0.033) . Among the 25 patients with p16 deletion, 14 underwent allo-HSCT and the median survival was 21 months, better than that of patients received chemotherapy alone (12 months) (P=0.030) . Conclusion: This study indicated that deletion of p16 was associated with poor prognosis in adult Ph(+) ALL, and the utility of second-generation TKI (Dasatinib) does not necessarily have an edge on efficacy over Imatinib, but allo-HSCT has the potential of elongating life expectancy. It is an important significance to define the status of p16 in Ph(+) ALL for predicting prognosis and guiding therapy decision-making. 目的:探讨p16基因缺失在成人Ph染色体阳性急性淋巴细胞白血病(Ph(+) ALL)中的临床意义。方法:回顾性分析80例Ph(+)ALL伴p16基因缺失患者的临床特征、免疫表型、细胞遗传学、分子生物学改变及其预后。结果: 31.3% Ph(+)ALL患者合并p16基因缺失;p16基因缺失组与非缺失组相比,初诊时高白细胞计数(WBC≥30×10(9)/L)更常见,高表达CD20,更易出现附加染色体异常,其中以累及7、8、19号染色体以及der(22)较为常见;两组诱导缓解率比较差异无统计学意义(P=0.033),p16基因缺失组患者治疗3个疗程后获BCR-ABL融合基因主要分子学反应(MMR)率和完全分子学反应(CMR)率均明显低于非缺失组(P值分别为0.034和0.036),且复发率明显高于非缺失组(P=0.033);p16基因缺失组使用伊马替尼联合化疗者和使用达沙替尼联合化疗者的MMR、CMR率及复发率差异均无统计学意义(P值均>0.05);p16基因缺失组患者3年总体生存(OS)率及无病生存(DFS)率分别为37.1%和12.4%,显著低于非缺失组的54.1%和45.9%(P值分别为0.037和0.026);25例p16基因缺失患者中14例行异基因造血干细胞移植(allo-HSCT),其中位OS时间为21个月,明显长于非移植组患者的12个月(P=0.030)。结论:成人Ph(+)ALL伴p16基因缺失患者预后相对较差,二代酪氨酸激酶抑制剂不能明显改善其疗效,但allo-HSCT能够改善部分患者的生存,明确p16基因缺失状态对于评估预后和指导临床治疗有重要意义。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. He BL, Xu N, Li YL, et al. [Clinical analysis of adult Philadelphia chromosome-positive acute lymphoblastic leukemia with p16 gene deletion]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28395443. doi:10.3760/cma.j.issn.0253-2727.2017.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。